PHIBRO ANIMAL HEALTH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.73 USD | +2.33% |
|
-4.29% | +9.93% |
| 12:58pm | Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million | DJ |
| 10:37am | Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,285 | 1,063 | 1,170 | 774.8 | 554.9 | 515.6 | - | - |
| Enterprise Value (EV) 1 | 1,530 | 1,358 | 1,170 | 1,117 | 948.5 | 819.7 | 815.4 | 786.5 |
| P/E ratio | 23.5 x | 31.7 x | 21.6 x | 15.8 x | 16.9 x | 34.4 x | 17.9 x | 14.5 x |
| Yield | 1.45% | 1.83% | 1.66% | 2.51% | 3.5% | 3.77% | 3.72% | 3.69% |
| Capitalization / Revenue | 1.55 x | 1.33 x | 1.4 x | 0.82 x | 0.57 x | 0.52 x | 0.5 x | 0.49 x |
| EV / Revenue | 1.85 x | 1.7 x | 1.4 x | 1.18 x | 0.97 x | 0.82 x | 0.79 x | 0.74 x |
| EV / EBITDA | 13 x | 13.3 x | 10.8 x | 10.1 x | 8.41 x | 6.97 x | 6.55 x | 6.4 x |
| EV / FCF | 17.4 x | 20 x | 14.9 x | - | - | 15.5 x | 21.5 x | 17.9 x |
| FCF Yield | 5.76% | 5% | 6.72% | - | - | 6.47% | 4.66% | 5.59% |
| Price to Book | 5.95 x | 5.65 x | - | 2.95 x | 1.96 x | 1.82 x | 1.7 x | 1.57 x |
| Nbr of stocks (in thousands) | 40,454 | 40,454 | 40,504 | 40,504 | 40,504 | 40,504 | - | - |
| Reference price 2 | 31.77 | 26.27 | 28.88 | 19.13 | 13.70 | 12.73 | 12.73 | 12.73 |
| Announcement Date | 27/08/19 | 26/08/20 | 25/08/21 | 24/08/22 | 30/08/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 828 | 800.4 | 833.4 | 942.3 | 977.9 | 997.7 | 1,029 | 1,062 |
| EBITDA 1 | 118 | 102.1 | 107.9 | 111.1 | 112.8 | 117.7 | 124.5 | 123 |
| EBIT 1 | 96.6 | 78.7 | 84.7 | 87.3 | 88.4 | 81.44 | 87.61 | 98.57 |
| Operating Margin | 11.67% | 9.83% | 10.16% | 9.26% | 9.04% | 8.16% | 8.52% | 9.28% |
| Earnings before Tax (EBT) 1 | 71.5 | 55.51 | 66.5 | - | 54.1 | 23 | 39 | 51 |
| Net income 1 | 54.7 | 33.55 | 54.4 | 49.18 | 32.6 | 15.16 | 28.8 | 35.8 |
| Net margin | 6.61% | 4.19% | 6.53% | 5.22% | 3.33% | 1.52% | 2.8% | 3.37% |
| EPS 2 | 1.350 | 0.8300 | 1.340 | 1.210 | 0.8100 | 0.3700 | 0.7100 | 0.8800 |
| Free Cash Flow 1 | 88.11 | 67.96 | 78.56 | - | - | 53 | 38 | 44 |
| FCF margin | 10.64% | 8.49% | 9.43% | - | - | 5.31% | 3.69% | 4.14% |
| FCF Conversion (EBITDA) | 74.67% | 66.53% | 72.81% | - | - | 45.04% | 30.52% | 35.78% |
| FCF Conversion (Net income) | 161.08% | 202.54% | 144.42% | - | - | 349.68% | 131.95% | 122.91% |
| Dividend per Share 2 | 0.4600 | 0.4800 | 0.4800 | 0.4800 | 0.4800 | 0.4800 | 0.4733 | 0.4700 |
| Announcement Date | 27/08/19 | 26/08/20 | 25/08/21 | 24/08/22 | 30/08/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 214.7 | 232.7 | 239.6 | 255.3 | 232.5 | 244.6 | 245.7 | 255 | 231.3 | 249.9 | 253.6 | 265.1 |
| EBITDA 1 | 22.5 | 29.1 | 28 | 31.53 | 22.13 | 30.9 | 27.4 | 32.3 | 18.7 | 29.5 | 37.68 | 40.43 |
| EBIT 1 | 16.8 | 23.3 | 21.8 | 25.5 | 16.1 | 24.8 | 21.3 | 26.2 | 12.2 | 23 | 21.56 | 24.31 |
| Operating Margin | 7.82% | 10.01% | 9.1% | 9.99% | 6.92% | 10.14% | 8.67% | 10.27% | 5.27% | 9.2% | 8.5% | 9.17% |
| Earnings before Tax (EBT) | 9.6 | - | - | - | - | 12.1 | 15.1 | 21.4 | -12 | - | - | - |
| Net income 1 | 6.5 | 17.5 | 17.69 | 7.487 | 3.9 | 7.2 | 10 | 11.5 | -8 | 1.3 | 9.849 | 12.01 |
| Net margin | 3.03% | 7.52% | 7.38% | 2.93% | 1.68% | 2.94% | 4.07% | 4.51% | -3.46% | 0.52% | 3.88% | 4.53% |
| EPS 2 | 0.1600 | 0.4300 | 0.4400 | 0.1800 | 0.1000 | 0.1800 | 0.2500 | 0.2800 | -0.2000 | 0.0300 | 0.2400 | 0.3000 |
| Dividend per Share | - | - | - | - | - | - | - | 0.1200 | - | - | - | - |
| Announcement Date | 02/11/21 | 09/02/22 | 04/05/22 | 24/08/22 | 09/11/22 | 08/02/23 | 03/05/23 | 30/08/23 | 08/11/23 | 07/02/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 245 | 296 | - | 342 | 394 | 304 | 300 | 271 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.073 x | 2.895 x | - | 3.076 x | 3.489 x | 2.584 x | 2.408 x | 2.203 x |
| Free Cash Flow 1 | 88.1 | 68 | 78.6 | - | - | 53 | 38 | 44 |
| ROE (net income / shareholders' equity) | 27.3% | 21.7% | 25.5% | 19.6% | 18% | 17.3% | 16.2% | 16.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 5.340 | 4.650 | - | 6.480 | 6.980 | 7.010 | 7.480 | 8.100 |
| Cash Flow per Share 2 | 1.160 | 1.470 | 1.930 | 1.880 | - | 1.100 | 1.250 | 1.740 |
| Capex 1 | 29.9 | 34 | 29.3 | - | - | 42 | 40 | 42 |
| Capex / Sales | 3.61% | 4.25% | 3.52% | - | - | 4.21% | 3.89% | 3.95% |
| Announcement Date | 27/08/19 | 26/08/20 | 25/08/21 | 24/08/22 | 30/08/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
12.73
USD
Average target price
10.75
USD
Spread / Average Target
-15.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.93% | 516M | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -3.06% | 3.12B | |
| +1.01% | 1.4B | |
| -17.27% | 1.34B | |
| -4.10% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B |
- Stock Market
- Equities
- PAHC Stock
- Financials Phibro Animal Health Corporation
